The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.
 
Mounzer E. Agha
No Relationships to Disclose
 
Adam D. Cohen
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Roche/Genentech; Takeda
Patents, Royalties, Other Intellectual Property - Novartis
 
Deepu Madduri
Honoraria - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Kinevant; Legend Biotech; Sanofi; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Kinevant; Legend Biotech; Sanofi; Takeda
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Regeneron
 
Yael C. Cohen
Employment - VBL Therapeutics
Leadership - VBL Therapeutics
Stock and Other Ownership Interests - VBL Therapeutics
Honoraria - Janssen; Medison; NeoPharm; Takeda
Consulting or Advisory Role - Medison; Takeda
Research Funding - Amgen
Patents, Royalties, Other Intellectual Property - VBL Therapeutics
 
Michel Delforge
Honoraria - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Sanofi; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Sanofi; Takeda
Speakers' Bureau - Bristol-Myers Squibb/Celgene
Research Funding - Amgen; Bristol-Myers Squibb/Celgene; Janssen; Sanofi; Takeda
 
Jens Hillengass
Employment - Roswell Park Cancer Institute
Honoraria - Adaptive Biotechnologies; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Biotech; Oncopeptides; OncoTracker; Sanofi; Skyline Diagnostics; Takeda
Research Funding - Celgene (Inst)
Travel, Accommodations, Expenses - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; Janssen Biotech; Rocket Medical; Takeda
 
Hartmut Goldschmidt
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Chugai Pharma; GlaxoSmithKline K.K.; Janssen-Cilag; Novartis; Sanofi
Consulting or Advisory Role - Adaptive Biotechnologies (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Janssen-Cilag (Inst); Sanofi (Inst); Takeda (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma Europe (Inst); Incyte (Inst); Janssen (Inst); Merck (Inst); Molecular Partners (Inst); MSD (Inst); Mundipharma (Inst); Novartis (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Novartis; Sanofi; Takeda
 
Katja Weisel
Honoraria - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen-Cilag; Karyopharm Therapeutics; Oncopeptides; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen-Cilag; Karyopharm Therapeutics; Sanofi; Takeda
Research Funding - Amgen (Inst); Celgene (Inst); Janssen-Cilag (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen-Cilag; Takeda
 
Marc-Steffen Raab
Honoraria - Amgen; Bristol-Myers Squibb; Janssen; Novartis; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Janssen; Novartis; Sanofi; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Janssen
Research Funding - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Heidelberg Pharma; Novartis; Sanofi
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Takeda
 
Christof Scheid
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; MSD; Novartis; Takeda
Consulting or Advisory Role - Amgen; Janssen; Roche
Research Funding - Janssen; Novartis; Takeda
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Novartis; Takeda
 
Jordan Mark Schecter
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Kevin C. De Braganca
Employment - Janssen Research & Development
 
Helen Varsos
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
Travel, Accommodations, Expenses - Janssen Research & Development
 
Liwei Wang
Stock and Other Ownership Interests - Legend Biotech
 
Martin Vogel
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Marlene Carrasco-Alfonso
Employment - Legend Biotech; Novartis
Stock and Other Ownership Interests - Abeona Therapeutics; Adaptimmune; Adverum; Akcea Therapeutics; Allogene Therapeutics; Alnylam; Arbutus Biopharma; Arrowhead Pharmaceuticals; Atara Biotherapeutics; Audentes Therapeutics; Legend Biotech; Novartis
 
Muhammad Akram
Employment - Legend Biotech
Stock and Other Ownership Interests - Legend Biotech
Research Funding - Legend Biotech
Travel, Accommodations, Expenses - Legend Biotech
Other Relationship - Legend Biotech
 
Xiaoling Wu
Employment - Legend Biotech
Stock and Other Ownership Interests - Bristol-Myers Squibb; Editas Medicine; Legend Biotech
Travel, Accommodations, Expenses - Legend Biotech
 
Tonia Nesheiwat
Employment - Legend Biotech
Stock and Other Ownership Interests - Legend Biotech
 
Hermann Einsele
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Novartis; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Novartis; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb; Celgene (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda; Takeda